Detection of different β-lactamases and their co-existence in gram negative bacteria isolated from clinical samples at a Tertiary care centre

Vedavati B. I¹, Halesh L.H², Mallikarjun Koppad³* 

¹Tutor, ²Professor and HOD, ³Associate Professor, Dept. of Microbiology, Shimoga Institute of Medical Sciences, Shivamogga, Karnataka, India

*Corresponding Author: Mallikarjun Koppad
Email: mallikarjun.koppad@rediffmail.com

Abstract

Introduction: Infections due to Gram-negative bacilli are increasing worldwide. The extended spectrum β-lactamases (ESBLs), AmpC β-lactamases and metallo β-lactamases (MBLs), have emerged as a cause of antibacterial resistance in Gram negative bacteria (GNB). β-lactamase producing GNB presents significant diagnostic and therapeutic challenge in the management of infection. So the present study was conducted to know the antibiogram of Gram negative bacterial isolates, to detect the different β-lactamases and their co-existence, to guide clinician to start appropriate antibiotic therapy for the management of infection.

Materials and Methods: A total of 150 Gram negative clinical isolates were identified and antibiotic susceptibility testing was done according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Detection of ESBL was done by the combined disk diffusion method as per CLSI guidelines. Detection of AmpC β-lactamase was done by phenyl boronic acid test. MBL was detected using EDTA disc potentiation test.

Result: Among 150 Gram negative bacteria studied, 26 (17.34%) were pure ESBL producer, 50 (33.34%) were pure AmpC producer. ESBL and AmpC co-existed in 16 (10.67%) isolates and AmpC and MBL co-occurred in 16 (10.67%) isolates.

Conclusion: Along with routine antibiotic sensitivity testing, special tests should be done to detect “hidden” resistance mechanisms for the effective management of infection.

Keywords: Antibiogram, β-lactamases, Extended spectrum β-lactamases (ESBLs), AmpCβ-lactamases, Metalloβ-lactamases (MBLs), Co-existence.

Introduction

Gram-negative bacteria pose a therapeutic problem in the hospital settings and also in the community as they have acquired resistance to multiple antibiotics. An increase use of - β lactam antibiotics in hospitals and community has created drug resistant pathogens leading to increased morbidity, mortality and health-care costs. Of the several mechanisms of resistance, the most widespread and most important is the cleaving of the β-lactam ring, which is mediated by β-lactamases.

In Gram negative organisms, β-lactamases namely extended spectrum β-lactamases (ESBLs), AmpC β-lactamases and metallo β-lactamases (MBLs) are the major cause of β-lactam resistance. ESBLs are enzymes that are able to hydrolyze a wide variety of penicillin and cephalosporin including third-generation cephalosporin and monobactams. However, the ESBL producing bacteria are susceptible to cephapicyclins, beta-lactam plus beta-lactamase inhibitor combination, and carbapenems. In addition; they often exhibit resistance to other classes of drugs such as aminoglycosides, co-trimoxazole, tetracycline and fluoroquinolones. Presence of AmpC in the same strains renders them resistant to cephapicyclins and beta-lactam plus beta-lactamase inhibitor combinations. Thus, they limit the therapeutic options. Recently, metallo-lactamases (MBLs) mediated resistance have emerged as one of the most feared resistance mechanisms due to their ability to hydrolyze virtually all β-lactam agents including carbapenems. Its spread on highly mobile gene elements in nosocomial pathogens limits the therapeutic options.

The presence of ESBLs and AmpC β-lactamases in a same isolate decreases the effectiveness of the beta-lactam(beta-lactamase inhibitor combinations, while MBLs and AmpC β-lactamases confer resistance to carbapenems. Often, these enzymes are co-expressed in the same isolate.

β-lactamase producing Gram-negative organisms presents significant diagnostic and therapeutic challenge in the management of infection. This emphasizes the need for the detection of isolates that co-produce β-lactamases and prevent therapeutic failures and nosocomial outbreaks and to decrease the length of stay in a hospital, to reduce healthcare costs and to formulate an effective antibiotic policy. So, the present study was undertaken to detect ESBL, AmpC β-lactamase, and metallo-β-lactamase in gram negative bacteria.

Aims and Objectives of the Study

1. To isolate and to study the antibiogram of gram negative bacterial isolates
2. To detect the different β-lactamases and their co-existence by using different substrates and inhibitors by disc potentiation method in Gram-negative bacteria isolated from various clinical samples.
3. To guide clinician to start appropriate antibiotic based on antibiogram and by knowing their beta lactamase production.
Materials and Methods

Present study was done at Shimoga Institute of Medical Sciences, Shivanagga, for four month duration from September 2018 to December 2018, after obtaining institutional ethical committee clearance.

The study was conducted on 150 Gram negative bacilli isolates from various clinical samples of patients received at Microbiology laboratory from McGann teaching hospital, attached to Shimoga institute of medical sciences. These samples were processed on blood agar, chocolate agar, and MacConkey agar media and incubated at 37°C under aerobic conditions. The organisms were identified as per standard conventional methods.13

Antimicrobial susceptibility testing of isolates were done on Muller-Hinton agar by Kirby-Bauer disc diffusion method, according to the Clinical and Laboratory Standards Institute (CLSI, 2018) guidelines.7 Susceptibility testing was carried out using the following antibiotics: Ampicillin (AMP), Ampicillin/sulbactam (A/S), Cefuroxime (CXM), Ceftazidine (CAZ), Co-trimoxazole (COT), Gentamicin (G), Chloramphenicol (c), Ciprofloxacin (CIP), Imipenem (IMP), Meropenem (MRP), Piperacilllin-tazobactam (PT), Amikacin (AK), Cefoxitin (cx), Cefepime (CPM), Aztreonam(AT).14

Detection of ESBL

Isolates showing decreased susceptibility to ceftazidime (zone diameter of ≤22mm) were selected for ESBL production. The CLSI double-disk diffusion test was performed for the confirmation of ESBL. Disk of ceftazidime (30μg) and ceftazidime/clavulanic acid (30/10 μg) were placed Mueller Hinton agar plate lawn inoculated with a 0.5 McFarland turbidity adjusted suspension of the test strain. After incubation, an enhanced zone of inhibition ≥5mm around ceftazidime/clavulanic acid in comparison with ceftazidime disc alone was confirmed as ESBL producer.4,11

Detection of AmpC β-lactamases

Isolates resistant to cefoxitin (30μg) were suspected to be AmpC producers. These isolates were subjected to phenyl boronic acid (PBA) disc enhancement method. In this method, two cefoxitin discs (30μg) were placed on Mueller Hinton agar plate lawn inoculated with a 0.5 McFarland turbidity adjusted suspension of the test strain. To one of the discs, 400 μg phenyl boronic acid was added. After overnight incubation at 37°C, enhancement of zone by 5mm around a cefoxitin disc with PBA, in comparison with a disc with cefoxitin alone, was taken as a positive result for AmpC production.4

Detection of Metallo- β-lactamases

The isolates resistant to imipenem were suspected to be MBL-producer. Confirmation for the detection of MBL was done by disc potentiation test with EDTA- impregnated imipenem discs. An increase in the zone size of atleast 7mm around the imipenem-EDTA disc compared to plain imipenem disc was considered as an MBL producer.4
Results

Present study was carried out in the department of microbiology, Shimoga Institute of Medical Sciences, Shivamogga. The observations made from the study are shown in following tables.

Table 1: Organisms isolated from clinical samples

| Organisms                  | N (%)   |
|----------------------------|---------|
| Escherichia coli           | 56 (37.34) |
| Klebsiella spp             | 40 (26.67) |
| Pseudomonas aeruginosa     | 24 (16.00) |
| Acinetobacter spp          | 16 (10.67) |
| Proteus spp                | 8 (5.34)  |
| Citrobacter spp            | 4 (2.60)  |
| Enterobacter spp           | 2 (1.34)  |
| Total                      | 150 ((100) |

Table 2: Organism-wise distribution of different beta lactamases and their co-production

| Organisms                  | Pure ESBL N (%) | Pure AmpC N (%) | ESBL+ AmpC N (%) | AmpC+ MBL N (%) | Non beta lactamase Producer N (%) | Total N (%) |
|----------------------------|-----------------|-----------------|------------------|----------------|----------------------------------|-------------|
| Escherichia coli           | 18 (12.00)      | 14 (9.34)       | 6 (4.00)         | 6 (4.00)       | 12 (8.00)                        | 56 (37.34)  |
| Klebsiella spp             | 4 (2.60)        | 12 (8.00)       | 8 (5.34)         | 4 (2.60)       | 12 (8.00)                        | 40 (26.67)  |
| Pseudomonas aeruginosa     | 2 (1.34)        | 16 (10.67)      | 0                | 2 (1.34)       | 4 (2.60)                         | 24 (16.00)  |
| Acinetobacter spp          | 2 (1.34)        | 6 (4.00)        | 2 (1.34)         | 2 (1.34)       | 4 (2.60)                         | 16 (10.67)  |
| Proteus spp                | 0               | 0               | 0                | 0              | 8 (5.34)                         | 8 (5.34)    |
| Citrobacter spp            | 0               | 0               | 0                | 2 (1.34)       | 2 (1.34)                         | 4 (2.60)    |
| Enterobacter spp           | 0               | 2 (1.34)        | 0                | 0              | 0                                | 2 (1.34)    |
|                            | 26 (17.34)      | 50 (33.34)      | 16 (10.67)       | 16 (10.67)     | 42 (28.00)                       | 150 ((100)  |

Among 150 Gram negative bacteria studied 26(17.34%) were pure ESBL producer, 50(33.34%) were pure AmpC producer. ESBL and AmpC co-occurred in 16(10.67%) isolates, AmpC and MBL co-occurred in 16(10.67%) isolates.
Table 3: Antibiotic sensitivity pattern of β-lactamase producing gram negative bacteria

| Antibiotics tested          | Escherichia coli N-48(%) | Klebsiella spp. N-28(%) | Acinetobacter spp. N-10(%) | Proteus spp N-0 | Citrobacter spp N-2(%) | Enterobacter spp N-2(%) | Pseudomonas spp N-20(%) |
|-----------------------------|--------------------------|--------------------------|----------------------------|-----------------|------------------------|------------------------|-------------------------|
| Ampicillin                  | 0                        | 0                        | -                          | 0               | 0                      | 0                      | -                       |
| Gentamicin                  | 28 (58.33)               | 10 (35.71)               | 6 (60.00)                  | -               | 0                      | 1 (50.00)              | 6 (30.00)               |
| Amikacin                    | 36 (75.00)               | 15 (53.57)               | 7 (70.00)                  | -               | 1 (50.00)              | 1 (50.00)              | 10 (50.00)              |
| Ampicillin/sulbactam        | 6 (12.50)                | 4 (14.28)                | 4 (40.00)                  | -               | 0                      | 0                      | -                       |
| Cefuroxime                  | 7 (14.58)                | 5 (17.85)                | 2 (20.00)                  | -               | 0                      | 0                      | -                       |
| Cefoxitin                   | 10 (20.83)               | 7 (25.00)                | 2 (20.00)                  | -               | 0                      | 0                      | -                       |
| Ceferpime                   | 10 (20.83)               | 10 (35.71)               | 6 (60.00)                  | -               | 1 (50)                 | 1 (50.00)              | 6 (30.00)               |
| Ciprofloxacin               | 24 (50.00)               | 15 (53.57)               | 4 (40.00)                  | -               | 2 (100)                | 0                      | 10 (50.00)              |
| Imipenem                    | 42 (87.50)               | 22 (78.57)               | 8 (80.00)                  | -               | 1 (50.00)              | 2 (100)                | 18 (90.00)              |
| Meropenem                   | 16 (33.34)               | 18 (64.28)               | 4 (40.00)                  | -               | 1 (50.00)              | 1 (50.00)              | 16 (80.00)              |
| Co-trimoxazole              | 16 (33.34)               | 7 (25.00)                | 0                          | -               | 0                      | 0                      | -                       |
| Aztreonam                   | 10 (20.83)               | 7 (25.00)                | 2 (20.00)                  | -               | 1 (50.00)              | 1 (50.00)              | 13 (65.00)              |
| Ceftazidime                 | 10 (20.83)               | 8 (28.57)                | 5 (50.00)                  | -               | 1 (50.00)              | 1 (50.00)              | 8 (40.00)               |
| Chloramphenicol             | 36 (75.00)               | 17 (60.71)               | 4 (40.00)                  | -               | 2 (100)                | 2 (100)                | -                       |
| Piperacillin-tazobactam     | -                        | -                        | -                          | -               | -                      | -                      | 9 (45.00)               |

Table 4: Aantibiotic sensitivity pattern of non-β-lactamase producer

| Antibiotics tested | Escherichia coli N-8(%) | Klebsiella spp. N-12(%) | Acinetobacter spp N-6(%) | Proteus spp N-8(%) | Citrobacter spp N-2(%) | Enterobacter spp N-0 | Pseudomonas spp N-4(%) |
|--------------------|--------------------------|--------------------------|--------------------------|-------------------|------------------------|----------------------|-----------------------|
| Ampicillin         | 0                        | 0                        | 0                        | 0                 | 0                      | 0                    | -                     |
| Gentamicin         | 7 (87.50)                | 8 (66.67)                | 4 (66.67)                | 4 (50.00)         | 2 (100)                | 0                    | 3 (75.00)             |
| Amikacin           | 6 (75.00)                | 8 (66.67)                | 4 (66.67)                | 4 (50.00)         | 2 (100)                | 0                    | 3 (75.00)             |
| Ampicillin/sulbactam| 0                        | 2 (16.67)                | 2 (33.34)                | 4 (50.00)         | 2 (100)                | 0                    | -                     |
| Cefuroxime         | 4 (50.00)                | 6 (50.00)                | 4 (66.67)                | 4 (50.00)         | 0                      | 0                    | -                     |
| Cefoxitin          | 5 (62.50)                | 6 (50.00)                | 5 (83.34)                | 7 (87.50)         | 2 (100)                | 0                    | -                     |
| Ceftazidime        | 7 (87.50)                | 9 (75.00)                | 5 (83.34)                | 7 (87.50)         | 2 (100)                | 0                    | 2 (50.00)             |
| Ciprofloxacin      | 6 (75.00)                | 9 (75.00)                | 4 (66.67)                | 6 (75.00)         | 2 (100)                | 0                    | 2 (50.00)             |
| Imipenem           | 8 (100)                  | 12 (100)                 | 6 (100)                  | 8 (100)           | 2 (100)                | 0                    | 4 (100)               |
| Meropenem          | 8 (100)                  | 9 (75.00)                | 5 (83.34)                | 7 (87.50)         | 2 (100)                | 0                    | 4 (100)               |
| Co-trimoxazole     | 6 (75.00)                | 7 (58.33)                | 4 (66.67)                | 5 (62.50)         | 1 (50.00)              | 0                    | -                     |
| Aztreonam          | 7 (87.50)                | 10 (83.34)               | 4 (66.67)                | 7 (87.50)         | 2 (100)                | 0                    | 4 (100)               |
| Ceftazidime        | 4 (50.00)                | 9 (75.00)                | 2 (33.34)                | 6 (75.00)         | 2 (100)                | 0                    | 2 (50.00)             |
| Chloramphenicol    | 6 (75.00)                | 9 (75.00)                | 5 (83.34)                | 7 (87.50)         | 2 (100)                | 0                    | -                     |
| Piperacillin-tazobactam | -                      | -                        | -                        | -                 | -                      | -                    | 3 (75.00)             |

Discussion
The β-lactamases, including extended-spectrum β-lactamases, Amp-C-β-lactamases, and metallo-β-lactamases, have emerged worldwide as a cause of antimicrobial resistance in Gram-negative bacteria (GNB). Often these enzymes are co-expressed in the same isolate and genes for all these three enzymes are often carried on plasmids, facilitating rapid spread between microorganisms.9 Emergence of β-lactamase producing Gram-negative organisms presents major diagnostic and therapeutic challenge in the management of infection.

In our study among 150 gram negative bacteria studied 26(17.34%) were pure ESBL producer, 50(33.34%) were pure AmpC producer. ESBL and AmpC co-occurred in 61(40.67%) isolates. AmpC and MBL co-occurred in 16(10.67%) isolates. The present study showed a high prevalence AmpC beta lactamases among various Gram negative bacteria isolated in our Hospital. Probably the risk factors for the colonization or infection with these organisms are due to prolonged hospital stay, intensive care unit admission, urinary and intravenous catheterization and exposure to antibiotics including extended spectrum cephalosporins.12

Study done at Uttarakhand, in 2013 reported among 184 gram negative bacteria studied 30 (16.3%) were pure ESBL producer, 26(14.1%) were pure AmpC producer., 60(32.6%) were pure MBL producer, ESBL and AmpC co-occurred in 42(22.8%) and AmpC and MBL co-occurred in 16(8.6%) isolates.2 Study done at Uttar Pradesh in 2007-2008 reported among 251 isolates studied, 138 (54.98%) were ESBL producers, 49 (19.52%) were AmpC producers and 45 (17.93%) were MBL producers.7 Study done in
Hyderabad in November 2010 to October 2011 reported of a total of 200 Gram negative isolates, pure ESBLs were seen in 50(25%) isolates and pure AmpC were seen in 35(17.5%) isolates. ESBL and AmpC co-existed in 38(19%) isolates. AmpC and MBL co-occurred in a single isolate.\(^4\)

In our study Antibiotic resistance was high among β-lactamase producers when compared to β-lactamase non producers which are comparable with study done at Pondicherry in 2011 and at Hyderabad in November 2010 to October 2011. This may be due to the fact that plasmids carrying these enzymes may carry co-resistance genes for other antibiotics.\(^5\)\(^5\)

The occurrence of multiple beta lactamases among gram negative bacteria limits the therapeutic options and poses diagnostic challenge to the microbiologist. The presence of ESBLs and AmpC beta-lactamases in a single isolate reduces the effectiveness of the beta-lactam–beta-lactamase inhibitor combinations, while MBLs and AmpC beta-lactamases confer resistance to carbapenems.\(^5\)\(^9\)

Detection of beta lactamases in GNB of great importance for epidemiological purposes as well as for infection control purposes and also helpful in management of infection with appropriate antibiotics.

Conclusion
If antibiotic susceptibility reports are being referred for treatment without testing of β-lactamases, it can result in serious therapeutic failures so along with routine antibiotic sensitivity testing, special tests should be done to detect these “hidden” resistance mechanisms. Detection of beta lactamases by phenotypic tests using various substrates and inhibitors are simple and easy to perform in a routine diagnostic laboratory.

Conflict of Interest: None.

References
1. Handa D, Pandey A, Asthana AK, Rawat A, Handa S. Thakuria B. Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli. Indian J Pathol Microbiol 2013;56:135-138.
2. Rawat V, Singhai M, Verma PK. Detection of different β-lactamases and their co-existence by using various discs combination methods in clinical isolates of Enterobacteriaceae and Pseudomonas spp. J Lab Physicians 2013;5:21-25.
3. K Anuradha, VV Sailaja, P Umabala, T Satheesh, V Lakshmi. Sensitivity pattern of gram negative bacilli to three β-lactam/β-lactamase inhibitor combinations using the automated api system. Indian J Med Microbiol 2007;25(3):203-208.
4. Vijaya Shivanna. Detection of co-existence of β-lactamases in Gram negative bacteria using disc potentiation tests. Indian J Microbiol Res 2017;4(1):64-67.
5. Sheemar S, Chopra S, Mahajan G, Kaur J, Chouhan YS. Extended spectrum beta-lactamase and AmpC producing Klebsiella pneumoniae: A therapeutic challenge. Trop J Med Res 2016;19:114-117.
6. Gajul SV, Mohite ST, Mangalgi SS, Wavare SM, Kakade SV. Klebsiella pneumoniae in septicemic neonates with special reference to extended spectrum β-lactamase, AmpC, metallo β-lactamase production and multiple drug resistance in tertiary care hospital. J Lab Physicians 2015;7:32-37.
7. Haider M, Rizvi M, Fatima N, Shukla I, Malik A. Necessity of detection of extended spectrum beta-lactamase, AmpC and metallo-beta-lactamases in Gram-negative bacteria isolated from clinical specimens. Muller J Med Sci Res 2014;5:23-28.
8. V. Kumar, M. R. Sen, C. Nagam, R. Gahlot, and S. Kumari. Burden of different beta-lactamase classes among clinical isolates of AmpC-producing Pseudomonas aeruginosa in burn patients: A prospective study. Indian J Crit Care Med 2012;16(3):136-140.
9. Chatterjee S S, Karmacharya R, Madhup S K, Gautam V, Das A, Ray P. High prevalence of co-expression of newer β-lactamases (ESBLs, Amp-C-β-lactamases, and metallo-β-lactamases) in gram-negative bacilli. Indian J Med Microbiol 2010;28:267-268.
10. Goel V, Hogade SA, Karadesai SG. Prevalence of extended-spectrum beta-lactamases, AmpC betalactamase, and metallo-beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii in an intensive care unit in a tertiary care hospital. J Sci Soc 2013;40:28-31.
11. Naveen Grover, A.K. Sahni, and S. Bhattacharya. Therapeutic challenges of ESBLs and AmpC beta-lactamase producers in a tertiary care center. Med J Armed Forces India 2013;69(1):4–10.
12. Sageerabanoo S, Malini A, Mangaiyarkarasi T, Hemalatha G. Phenotypic detection of extended spectrum β-lactamase and Amp-C β-lactamase producing clinical isolates in a Tertiary Care Hospital: A preliminary study. J Nat Sc Biol Med 2015;6:383-387.
13. Collee JG, Marr W. Culture of bacteria. Mackie and McCartney Practical medical microbiology. 14th edn. Edinburg: Churchill Livingstone.1996:95-149.
14. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 28th ed. Informational Supplement. CLSI document M100-S25, Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
15. Shoorashetty R M, Nagarathnamma T, Prathibha J. Comparison of the boronic acid disk potentiation test and ceftazidime-clavulanic acid method for the detection of ESBL among AmpC-producing Enterobacteriaceae. Indian J Med Microbiol 2011;29:297-301.

How to cite this article: Vedavati BI, Halesh LH, Koppad M. Detection of different β - lactamases and their co-existence in gram negative bacteria isolated from clinical samples at a Tertiary care centre. Indian J Microbiol Res 2019;6(1):61-65.